Estrogen for Alzheimer’s disease in women: Randomized, double-blind, placebo-controlled trial
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: AD, the most prevalent cause of dementia, affects twice as many women as men. Therapeutic options are limited, but results of prior studies support the hypothesis that estrogen treatment may improve symptoms of women with this disorder. METHODS: Forty-two women with mild-to-moderate dementia due to AD were enrolled into a randomized, double-blind, placebo-controlled, parallel-group trial of unopposed conjugated equine estrogens (1.25 mg/day) for 16 weeks. RESULTS: Outcome data were available for 40 women at 4 weeks and 36 women at 16 weeks. At both 4 and 16 weeks, there were no significant differences or statistical trends between treatment groups on the primary outcome measure (the cognitive subscale of the Alzheimer's Disease Assessment Scale), clinician-rated global impression of change, or caregiver-rated functional status. Exploratory analyses of mood and specific aspects of cognitive performance also failed to demonstrate substantial group differences. CONCLUSION: Although conclusions are limited by small sample size and the possibility of a type II error, results suggest that short-term estrogen therapy does not improve symptoms of most women with AD. These findings do not address possible long-term effects of estrogen in AD, possible interactions between estrogen and other treatment modalities, or putative effects of estrogen in preventing or delaying onset of this disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
Lawton, M. P., & Brody, E. M. (1969) · The Gerontologist · doi:10.1093/geront/9.3_part_1.179 · Cited by 18,540
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Comparative distribution of estrogen receptor-? and -? mRNA in the rat central nervous system
Shughrue, P. J., Lane, M. V., & Merchenthaler, I. (1997) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19971201)388:4<507::aid-cne1>3.0.co;2-6 · Cited by 2,259
Brookmeyer, R., Gray, S., & Kawas, C. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,787
Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
Tang, M.-X., Jacobs, D., Stern, Y., Marder, K., Schofield, P., Gurland, B., Andrews, H., & Mayeux, R. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03356-9 · Cited by 1,647
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Self-citationPathological verification of ischemic score in differentiation of dementias
Rosen, W. G., Terry, R. D., Fuld, P. A., Katzman, R., & Peck, A. (1980) · Annals of Neurology · doi:10.1002/ana.410070516 · Cited by 1,273
Cited by
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
Physical activity and risk of cognitive impairment and dementia in elderly persons
Laurin, D., Verreault, R., Lindsay, J., MacPherson, K., & Rockwood, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.498 · Cited by 1,561
Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
Adult neurogenesis: from precursors to network and physiology
Abrous, D. N., Koehl, M., & Le Moal, M. (2005) · Physiological Reviews · doi:10.1152/physrev.00055.2003 · Cited by 971
Garcia-Segura, L. M., Azcoitia, I., & DonCarlos, L. L. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00025-3 · Cited by 938
Zandi, P. P. (2002) · JAMA · doi:10.1001/jama.288.17.2123 · Cited by 906
Gillies, G. E., & McArthur, S. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002071 · Cited by 733
“AD, like PD, is a multifactorial disease, the underlying causes of which are unknown; unlike PD, however, being female rather than male features among a number of risk factors, after aging, for developing the disease (Henderson et al., 2000; Pike et al., 2009).”
BackgroundPostmenopausal Hormone Therapy: An Endocrine Society Scientific Statement
Santen, R. J., Allred, D. C., Ardoin, S. P., Archer, D. F., Boyd, N., Braunstein, G. D., Burger, H. G., Colditz, G. A., Davis, S. R., Gambacciani, M., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2509 · Cited by 680
Self-citationHormone Replacement Therapy and Cognition: Systematic Review and Meta-analysis
LeBlanc, E. S., Janowsky, J., Chan, B. K. S., & Nelson, H. D. (2001) · JAMA · doi:10.1001/jama.285.11.1489 · Cited by 659
Borrás, C., Sastre, J., García-Sala, D., Lloret, A., Pallardó, F. V., & Viña, J. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)01356-4 · Cited by 654
Neurotrophic and neuroprotective actions of estrogen: Basic mechanisms and clinical implications
Brann, D. W., Dhandapani, K., Wakade, C., Mahesh, V. B., & Khan, M. M. (2007) · Steroids · doi:10.1016/j.steroids.2007.02.003 · Cited by 647
Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Estrogen and cognitive functioning in women
Sherwin, B. B. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0016 · Cited by 560
Estrogen: A master regulator of bioenergetic systems in the brain and body
Rettberg, J. R., Yao, J., & Brinton, R. D. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.08.001 · Cited by 534
“The prevailing data indicate that although HT cannot alter the progression of AD (Asthana et al., 2001, 1999; Henderson et al., 2000; Mulnard et al., 2000; Wang et al., 2000), it may have the potential to lower the risk of women developing AD in the first place (Wise et al., 2001).”
Protective actions of sex steroid hormones in Alzheimer’s disease
Pike, C. J., Carroll, J. C., Rosario, E. R., & Barron, A. M. (2009) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2009.04.015 · Cited by 522
Rockwood, K., Kirkland, S., Hogan, D. B., MacKnight, C., Merry, H., Verreault, R., Wolfson, C., & McDowell, I. (2002) · Archives of Neurology · doi:10.1001/archneur.59.2.223 · Cited by 516
E PIDEMIOLOGY OF N EURODEGENERATION
Mayeux, R. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.043002.094919 · Cited by 515
Soy, Soy Foods and Their Role in Vegetarian Diets
Rizzo, G., & Baroni, L. (2018) · Nutrients · doi:10.3390/nu10010043 · Cited by 498
Oestrogen as a neuroprotective hormone
Behl, C. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn846 · Cited by 488
Hogervorst, E., Williams, J., Budge, M., Riedel, W., & Jolles, J. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00410-3 · Cited by 439
Zaheer, K., & Humayoun Akhtar, M. (2017) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2014.989958 · Cited by 411
Lin, J. S., O’Connor, E., Rossom, R. C., Perdue, L. A., & Eckstrom, E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-9-201311050-00730 · Cited by 410
Estrogen, Menopause, and the Aging Brain: How Basic Neuroscience Can Inform Hormone Therapy in Women
Morrison, J. H., Brinton, R. D., Schmidt, P. J., & Gore, A. C. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3369-06.2006 · Cited by 386
The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications
Brinton, R. D. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.07.003 · Cited by 385
Practice parameter: Management of dementia (an evidence-based review)
Oken, B. S. (2001) · Neurology · doi:10.1212/wnl.57.12.2323 · Cited by 351
Alzheimer's Disease and Mild Cognitive Impairment
Kelley, B. J., & Petersen, R. C. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.008 · Cited by 326
Gender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice
Wang, J., Tanila, H., Puoliväli, J., Kadish, I., & Groen, T. V. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.08.009 · Cited by 316
Patnode, C. D., Perdue, L. A., Rossom, R. C., Rushkin, M. C., Redmond, N., Thomas, R. G., & Lin, J. S. (2020) · JAMA · doi:10.1001/jama.2019.22258 · Cited by 309
Steroid hormones and neurosteroids in normal and pathological aging of the nervous system
Schumacher, M., Weill-Engerer, S., Liere, P., Robert, F., Franklin, R. J. M., Garcia-Segura, L. M., Lambert, J. J., Mayo, W., Melcangi, R. C., Parducz, A., et al. (2003) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2003.09.004 · Cited by 300
Hormone Therapy and Risk of Alzheimer Disease: A Critical Time
Resnick, S. M., & Henderson, V. W. (2002) · JAMA · doi:10.1001/jama.288.17.2170 · Cited by 287
Self-citationFemales exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model
Hirata-Fukae, C., Li, H.-F., Hoe, H.-S., Gray, A. J., Minami, S. S., Hamada, K., Niikura, T., Hua, F., Tsukagoshi-Nagai, H., Horikoshi-Sakuraba, Y., et al. (2008) · Brain Research · doi:10.1016/j.brainres.2008.03.079 · Cited by 284
Lyketsos, C. G., Colenda, C. C., Beck, C., Blank, K., Doraiswamy, M. P., Kalunian, D. A., & Yaffe, K. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000221334.65330.55 · Cited by 275
Brain aromatase is neuroprotective
Azcoitia, I., Sierra, A., Veiga, S., Honda, S., Harada, N., & Garcia‐Segura, L. M. (2001) · Journal of Neurobiology · doi:10.1002/neu.1038 · Cited by 273
Morphological abnormalities in the brains of estrogen receptor β knockout mice
Wang, L., Andersson, S., Warner, M., & Gustafsson, J.-Å. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041617498 · Cited by 272
Sexual dimorphism in predisposition to Alzheimer's disease
Fisher, D. W., Bennett, D. A., & Dong, H. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.04.004 · Cited by 270
Borrás, C., Gambini, J., Gómez‐Cabrera, M. C., Sastre, J., Pallardó, F. V., Mann, G. E., & Viña, J. (2005) · Aging Cell · doi:10.1111/j.1474-9726.2005.00151.x · Cited by 269
Enhanced Verbal Memory in Nondemented Elderly Women Receiving Hormone-Replacement Therapy
Maki, P. M., Zonderman, A. B., & Resnick, S. M. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.227 · Cited by 269
The Glutamatergic System and Alzheimer???s Disease: Therapeutic Implications
Butterfield, D. A., & Pocernich, C. B. (2003) · CNS Drugs · doi:10.2165/00023210-200317090-00004 · Cited by 267
High-dose estradiol improves cognition for women with AD: Results of a randomized study
Asthana, S., Baker, L. D., Craft, S., Stanczyk, F. Z., Veith, R. C., Raskind, M. A., & Plymate, S. R. (2001) · Neurology · doi:10.1212/wnl.57.4.605 · Cited by 266
Turgeon, J. L., Carr, M. C., Maki, P. M., Mendelsohn, M. E., & Wise, P. M. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0020 · Cited by 264
Minireview: Neuroprotective Effects of Estrogen--New Insights into Mechanisms of Action
Wise, P. M. (2001) · Endocrinology · doi:10.1210/en.142.3.969 · Cited by 259
Estrogen Alters Spine Number and Morphology in Prefrontal Cortex of Aged Female Rhesus Monkeys
Hao, J., Rapp, P. R., Leffler, A. E., Leffler, S. R., Janssen, W. G. M., Lou, W., McKay, H., Roberts, J. A., Wearne, S. L., Hof, P. R., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3440-05.2006 · Cited by 257
Antioxidants as treatment for neurodegenerative disorders
Moosmann, B., & Behl, C. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.10.1407 · Cited by 252
Estrogen therapy and cognition: a review of the cholinergic hypothesis
Gibbs, R. B. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0036 · Cited by 206
Zhao, L., & Brinton, R. D. (2007) · Brain Research · doi:10.1016/j.brainres.2007.06.092 · Cited by 205
The Cognitive Neuroscience of Development
(2005) · Psychology Press eBooks · doi:10.4324/9780203989395 · Cited by 192
Murray, H. E., Pillai, A. V., McArthur, S. R., Razvi, N., Datla, K. P., Dexter, D. T., & Gillies, G. E. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00578-x · Cited by 189
Genetic and host factors for dementia in Down's syndrome
Schupf, N. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.405 · Cited by 188
Sullivan Mitchell, E., & Fugate Woods, N. (2001) · Journal of Women's Health & Gender-Based Medicine · doi:10.1089/152460901750269670 · Cited by 188
“22,23 Thus, the evidence for a protective effect of estrogen on cognitive function is based mainly on descriptive studies or small placebo-controlled studies.”
Cognitive dysfunction with aging and the role of inflammation
Simen, A. A., Bordner, K. A., Martin, M. P., Moy, L. A., & Barry, L. C. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622311399145 · Cited by 177
“Similarly, Henderson and colleagues randomized 42 women with AD to estrogen versus placebo for 16 weeks and no differences were detected [Henderson et al. 2000].”
MethodNeuroplasticity in Alzheimer's disease
Teter, B., & Ashford, J. W. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10441 · Cited by 170
Bone Mineral Density and the Risk of Alzheimer Disease
Tan, Z. S., Seshadri, S., Beiser, A., Zhang, Y., Felson, D., Hannan, M. T., Au, R., Wolf, P. A., & Kiel, D. P. (2005) · Archives of Neurology · doi:10.1001/archneur.62.1.107 · Cited by 123
Schoenmaker, N., & Van Gool, W. A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00884-1 · Cited by 86
Yoon, B.-K., Kim, D. K., Kang, Y., Kim, J.-W., Shin, M.-H., & Na, D. L. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04666-6 · Cited by 35
Szegő, É. M., Csorba, A., Janáky, T., Kékesi, K. A., Ábrahám, I. M., Mórotz, G. M., Penke, B., Palkovits, M., Murvai, Ü., Kellermayer, M. S. Z., et al. (2011) · Neuroendocrinology · doi:10.1159/000321119 · Cited by 24
Metadata
- Authors
- Henderson, V. W., Paganini-Hill, A., Miller, B. L., Elble, R. J., Reyes, P. F., Shoupe, D., McCleary, C. A., Klein, R. A., Hake, A. M., & Farlow, M. R.
- Venue
- Neurology
- Published
- 2000-01-25
- Volume
- 54
- Issue
- 2
- Pages
- 295-295
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2128007559
- Cited by
- 550
- References
- 38
- FWCI
- 54.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.